$1.22
0.83% yesterday
Nasdaq, Jun 26, 10:00 pm CET
ISIN
IE00BF3W0Q35
Symbol
ITRM
Sector
Industry

Iterum Therapeutics Plc Share price

$1.22
-0.13 9.63% 1M
-0.52 29.68% 6M
-0.75 38.07% YTD
+0.15 14.02% 1Y
-34.33 96.57% 3Y
-92.53 98.70% 5Y
-191.53 99.37% 10Y
Nasdaq, Closing price Wed, Jun 26 2024
ISIN
IE00BF3W0Q35
Symbol
ITRM
Sector
Industry

Key figures

Market capitalization $20.20m
Enterprise Value $22.54m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-45.10m
Free cash flow (TTM) Free cash flow $-42.63m
Cash position $18.21m
EPS (TTM) EPS $-2.64
P/E ratio expected negative
Short interest 7.68%
Show more

Is Iterum Therapeutics Plc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,947 shares worldwide.

Iterum Therapeutics Plc Share analysis

Unlock scores for free

Analyst opinions

2 Analysts have issued a Iterum Therapeutics Plc forecast:

2x Buy
100%

Analyst opinions

2 Analysts have issued a Iterum Therapeutics Plc forecast:

Buy
100%

Financial data from Iterum Therapeutics Plc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 1.32 1.32
26% 26%
-
-1.32 -1.32
26% 26%
-
- Selling and administrative expenses 6.24 6.24
32% 32%
-
- Research and development costs 36 36
92% 92%
-
-44 -44
47% 47%
-
- Depreciation and amortization 1.32 1.32
26% 26%
-
EBIT (operating result) EBIT -45 -45
43% 43%
-
Net profit -36 -36
30% 30%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Iterum Therapeutics Plc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Iterum Therapeutics Plc Share News

Neutral
GlobeNewsWire
6 days ago
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the U.S. Food and Drug Administration (FDA) has determi...
Neutral
GlobeNewsWire
27 days ago
Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024 Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024
Neutral
Seeking Alpha
about one month ago
Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey N. Fishman - CEO Judith M.
More Iterum Therapeutics Plc News

Company profile

Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Corey Fishman
Employees 14
Founded 2015
Website www.iterumtx.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now